Teaching & Academic Contributions
- PharmD Courses:
- P162: Pharmaceutics II (as coordinator)
- P172: Pharmacy Lab II (as coordinator)
- Graduate Teaching:
- PS8584: Advanced Drug ang Gene Delivery Systems (as co-coordinator)
Research Focus & Interests
Dr. Ho-Lun Wong specializes in developing nanomedicine and targeted drug delivery, specifically, lipid-based and polymer/lipid hybrid nanosystems, to deliver small molecules, large molecules (e.g. RNA therapeutics and proteins) and their combinations for treatment of the diseases that are drug-resistant and/or poorly accessible by conventional drug therapy, with focus on the infectious diseases such as antibiotic-resistant bacteria and HIV. The key objective is to maximize delivery of drug to the desirable sites at desirable timing, so significantly enhanced efficacy and improved safety of treatment can become achievable.
- Key Interests: Hybrid nanocarriers, lipid nanocarriers, targeted drug delivery, antibiotic-resistant bacterial diseases, HIV reservoir treatment
Select Publications
- Wu D, Si M, Xue HY, Khalili K, Kaminski R, Wong HL. Lipid nanocarrier targeting activated macrophages for antiretroviral therapy of HIV reservoir. Nanomedicine. 18(20):1343-1360, 2023. (lipid nanocarrier for HIV reservoir treatment)
- Guo P, Si M, Wu D, Xue HY, Hu W, Wong HL. Incorporation of docosahexaenoic acid (DHA) enhances nanodelivery of antiretroviral across the blood-brain barrier for treatment of HIV reservoir in brain. Journal of Controlled Release. 328:696-709, 2020. (lipid nanocarrier to target blood-brain barrier)
- Guo P, Buttaro B, Xue HY, Tran NT, Wong HL. Lipid-polymer hybrid nanoparticles carrying linezolid improve treatment of methicillin-resistant Staphylococcus aureus (MRSA) harbored inside bone cells and biofilms. European Journal of Pharmaceutics and Biopharmaceutics. 151:189-198, 2020. (hybrid nanocarrier for advanced MRSA treatment)
Practice & Service
- University Research and Creative Achievement Award Committee, Temple University